FCOMV
CMPX icon

Foresite Capital Opportunity Management V’s Compass Therapeutics CMPX Stock Holding History

Foresite Capital Opportunity Management V’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$3.54M Hold
1,554,250
– – 10.64% 4
2022
Q2 		$4.12M Buy
1,554,250
+454,250
+41% +$986K 10.38% 3
2022
Q1 		$1.51M Hold
1,100,000
– – 2.11% 10
2021
Q4 		$3.49M Buy
+1,100,000
New +$3.65M 2.34% 8

Other funds holding CMPX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Foresite Capital Opportunity Management V's CMPX Position: Q3 2022 in Review

Foresite Capital Opportunity Management V held its Compass Therapeutics (CMPX) position steady in Q3 2022 at 1,554,250 shares worth $3.54M. The position accounts for 10.64% of the portfolio, ranked #4.

Foresite Capital Opportunity Management V first reported a position in CMPX in Q4 2021 and has held it in 4 quarters since. The position peaked at $4.12M in Q2 2022. 38 funds tracked by Wall St. Rank hold CMPX as of Q3 2022.

  • Foresite Capital Opportunity Management V held 1,554,250 shares of Compass Therapeutics worth $3.54M as of Q3 2022.
  • Foresite Capital Opportunity Management V left its Compass Therapeutics share count unchanged in Q3 2022.
  • Compass Therapeutics made up 10.64% of Foresite Capital Opportunity Management V's portfolio in Q3 2022, its #4 holding.
  • Foresite Capital Opportunity Management V first reported a position in Compass Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • Foresite Capital Opportunity Management V's Compass Therapeutics position peaked at $4.12M in Q2 2022.
  • 38 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2022.

Based on Foresite Capital Opportunity Management V's 13F filing for Q3 2022, filed 14 Nov 2022.